SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

Abstract Background HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The scaffold protein SH3-domain-binding glutamic acid-rich protein-like prote...

Full description

Bibliographic Details
Main Authors: Hui Li, Mingming Zhang, Yanli Wei, Farhan Haider, Yitong Lin, Wen Guan, Yanbin Liu, Shaoyang Zhang, Ronghua Yuan, Xia Yang, Shulan Yang, Haihe Wang
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
SH3BGRL
HER2
Breast cancer
Drug resistance
Online Access:http://link.springer.com/article/10.1186/s13046-020-01577-z

Internet

http://link.springer.com/article/10.1186/s13046-020-01577-z

Similar Items